624 related articles for article (PubMed ID: 12518324)
1. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
2. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
3. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Oliver P; Zhang Z; Agrawal S; Zhang R
Ann N Y Acad Sci; 2003 Dec; 1002():217-35. PubMed ID: 14751837
[TBL] [Abstract][Full Text] [Related]
6. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
Prasad G; Wang H; Agrawal S; Zhang R
Anticancer Res; 2002; 22(1A):107-16. PubMed ID: 12017271
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
Zhang Z; Li M; Wang H; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
[TBL] [Abstract][Full Text] [Related]
9. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization by antisense oligonucleotides targeting MDM2.
Bianco R; Ciardiello F; Tortora G
Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
[TBL] [Abstract][Full Text] [Related]
12. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
Mu Z; Hachem P; Agrawal S; Pollack A
Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
[TBL] [Abstract][Full Text] [Related]
13. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
Zhang R; Wang H; Agrawal S
Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
[TBL] [Abstract][Full Text] [Related]
14. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
[TBL] [Abstract][Full Text] [Related]
15. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
[TBL] [Abstract][Full Text] [Related]
16. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
Wang H; Hang J; Shi Z; Li M; Yu D; Kandimalla ER; Agrawal S; Zhang R
Int J Oncol; 2002 Jul; 21(1):73-80. PubMed ID: 12063552
[TBL] [Abstract][Full Text] [Related]
18. Novel MDM2 p53-independent functions identified through RNA silencing technologies.
Zhang Z; Wang H; Li M; Rayburn E; Agrawal S; Zhang R
Ann N Y Acad Sci; 2005 Nov; 1058():205-14. PubMed ID: 16394138
[TBL] [Abstract][Full Text] [Related]
19. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
20. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.
Tortora G; Caputo R; Damiano V; Bianco R; Chen J; Agrawal S; Bianco AR; Ciardiello F
Int J Cancer; 2000 Dec; 88(5):804-9. PubMed ID: 11072252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
